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Background. High, or increasing, rates of invasive Haemophilus influenzae (Hi) type a disease have been
reported from North American native children from circumpolar regions, raising the question of serotype
replacement being driven by vaccination against Hi type b (Hib). Indigenous Australians from remote areas
had high rates of invasive Hib disease in the past, comparable to those in North American Indigenous
populations.
Objective. Evaluate incidence rates of invasive Hi (overall and by serotype) in Indigenous Australian children
over time.
Design. Descriptive study of Hi incidence rates by serotype, in the Northern Territory (NT) and
South Australia (SA) from 2001 to 2011. Comparison of NT data with a study that was conducted in the
NT in 19851988, before Hib vaccine was introduced.
Results. The average annual rate of invasive Hi type a (Hia) disease in Indigenous children agedB5 years was
11/100,000 population. Although the incidence of Hi infection in Indigenous children in 20012003 was lower
than during 20042011, this may be due to changes in surveillance. No other trend over time in individual
serotypes or total invasive Hi disease, in Indigenous or non-Indigenous people, was identified. Compared to
19851988, rates in 20012011 were lower in all serotype groupings, by 98% for Hib, 75% for Hia, 79% for
other serotypes and 67% for non-typeable Hi.
Conclusions. There is no evidence of increases in invasive disease due to Hia, other specific non-b types,
or non-typeable Hi in Australian Indigenous children. These data suggest that the increase in Hia some time
after the introduction of Hib vaccine, as seen in the North American Arctic Region, is not common to
all populations with high pre-vaccine rates of invasive Hib disease. However, small case numbers and the
lack of molecular subtyping and PCR confirmation of pre-vaccine results complicate comparisons with
North American epidemiology.
Keywords: Haemophilus inﬂuenza; oceanic ancestry group; epidemiology
A
lthough the climate of Central and Northern
Australia is very different to that in the circum-
polar region, the Indigenous people of these
2 regions share many similarities. These include the
social determinants that lead to ill-health, such as poor
environmental living conditions, poverty and remoteness
(1,2). Consequently, remote Indigenous Australian and
North American peoples have been afflicted with very
high rates of respiratory disease, including invasive
bacterial diseases, pneumonia and otitis media. In the
case of invasive Haemophilus influenzae (Hi) and pneu-
mococcal disease, this has included broader serotype
distributions, making disease control by vaccination
more challenging although still successful overall (3).
South Australia (SA) has a population of 1.6 million
including 31,000 Aboriginal and Torres Strait Islander
(henceforth referred to as ‘‘Indigenous’’) people, and
covers an area of 380,000 square miles. The population
is concentrated in the capital city Adelaide (1.2 million).
The population of the Northern Territory (NT) is much
smaller at 235,000, including 70,000 Indigenous people.
The capital Darwin has 128,000 residents. The NT covers
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(page number not for citation purpose)an area of 521,000 square miles. The majority of the
landmass covered by these 2 jurisdictions is classified
by the Australian Bureau of Statistics as ‘‘very remote’’
(Fig. 1). The climate is subtropical in the north, arid
with wide temperature fluctuations in the centre, and
Mediterranean on the coastal fringe in the south. It
includes most of central Australia, from where the highest
rates of Hi type b (Hib) and pneumococcal disease in the
world were recorded in Aboriginal children (4,5).
Hib vaccine was recommended and funded for all
Australian infants from 1993, and since 2001, more than
90% of infants have completed the primary course by 12
months of age (6). In recent years, it has been suggested
that the rates of invasive disease due to Hi type a (Hia)
have been increasing in North American Indigenous
children, particularly in the circumpolar region (7).
Capsular switching of a virulence factor from serotype
b to serotype a has also been demonstrated (8), and
the possibility of a role of the Hib vaccine in causing
serotype replacement has been discussed (9). Molecular
testing has shown the predominance of a particular clone
in Northern Canada and Alaska (10).
This study aims to examine rates of disease due to Hi,
in particular, serotype a, in remote Australian Indigenous
people, and to examine whether increases in Hia in the
post-Hib vaccine era can be demonstrated in Australia.
Methods
Invasive Hib infection has been reportable in SA and
the NT since 1993. This was expanded to include all
invasive Hi, by all public and private laboratories in
the NT and by laboratories and medical practitioners in
SA. Case reporting occurred as part of routine passive
infectious disease surveillance. Although no formal
audits have been conducted, surveillance coordinators
(authors Peter Markey and Ann P. Koehler) consider
surveillance processes to have been stable and satisfac-
tory from 2001. Reporting is almost exclusively direct
from laboratories to health authorities, with subsequent
follow-up to medical practitioners. Clinical information is
not collected.
Invasive Hi isolates from laboratories in these jurisdic-
tions were referred for serotyping to IMVS Pathology in
Adelaide or the Institute of Clinical and Pathological
Medicine Research, Westmead (ICPMR), Sydney. Sero-
typing at ICPMR was done using serum coagglutination
test kits: Phadebact Haemophilus Test (Bactus, Sweden)
consisting of monovalent b antisera and polyvalent a, cf
antisera and Remel Hi agglutinating sera  monovalent a,
cf. Unusual or weak reactions were checked by PCR.
In recent years, the PCR method was a multiplex that
included an H (capsule-specific) target and type-specific
genes for Hia and Hib. ICPMR laboratory was enrolled
Fig. 1. Australia by ‘‘remoteness classiﬁcation’’. Source: Australian Bureau of Statistics.
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gram, Haemophilus Reference Laboratory, Respiratory
& Systemic Infection Laboratory, Health Protection
Agency, UK, until recently when the programme ended.
Serotyping at IMVS was done using Remel serum
agglutination test kits for monovalent b, polyvalent a,
cf and monovalent a, cf. No molecular testing or QA
programme was undertaken.
Incidence rates were calculated using population
estimates for relevant years from the Australian Bureau
of Statistics (11). Rates were compared using the rate
ratio and 95% confidence intervals, calculated using
the method of Rothman (12). The Chi-squared test
was used for testing the significance of differences in
proportions.
Average annual incidence rates in NT Indigenous
children for 20012011 were compared with a study
from the pre-vaccine erathat covered the same geographic
area (13). This was the only pre-vaccine study that
provided disease rates on all Hi serotypes in Indigenous
Australian children. It consisted of an audit of Hi cases
occurring in children agedB5 years from all 5 hospital
laboratories in the NT from 1985 to 1988, which included
samples referred from parts of the central desert region
of SA. There were 108 cases identified, 80 of which were
in Indigenous children. Testing was conducted at mul-
tiple hospitals using Wellcogen (Wellcome Diagnostics,
Dartford, England) latex agglutination or Phadebact
serum coagglutination test kits for monovalent b. Non-
type b isolates were forwarded to the IMVS laboratory
in Adelaide (formerly Adelaide Children’s Hospital) for
serotyping using Wellcogen monovalent antisera.
Results
There were a total of 238 cases of invasive Hi infection
reported from 2001 to 2011 in the 2 jurisdictions, 86 from
the NTand 152 from SA (Table I). Indigenous status was
unknown in 13 cases, 12 of which were from SA.
Annualised invasive Hi incidence rates for Indigenous
people were 10.5/100,000 (74 cases) in the NT and 7.1
(22) in SA, which were not significantly different (rate
ratio 1.5, 95% CI 0.92.5). There was also no significant
difference between the 2 jurisdictions in rates for non-
Indigenous people, which were 0.74 (12 cases) and 0.70
(117), respectively (rate ratio 1.1, 0.51.9).
Serotyping results were available for 215 (96%) isolates
with known Indigenous status (Table I). Of cases in
Indigenous children aged B5 years with a known
serotype 10/32 (30%), 2/6 (33%) were type a in the NT
and in SA, respectively. In non-Indigenous people,
the most commonly identified capsular type was non-
typeable, in both the NT 3/8 (38%) and in SA 89/111
(80%) and these proportions were significantly different
(P0.005). The data from here on were analysed for the
2 jurisdictions combined, as the serotype distribution
was similar in the 2 jurisdictions for the group of pri-
mary interest (Indigenous children), while cases in non-
Indigenous people were representative of an urban
population, predominantly from Adelaide.
The rates of Hi infection were higher in Indigenous
compared to non-Indigenous people (rate ratio 13.8, 95%
CI 10.418.0). In both groups, rates were highest in the
extremities of age. Serotype distributions differed be-
tween age groups and Indigenous status (Table I). Non-
typeable Hi isolates were most commonly identified
overall, making up 44% of isolates sent for typing from
Indigenous and 77% from non-Indigenous people. How-
ever, in children B5 years of age, non-typeable types were
less likely to be found (27 and 40% of cases in Indigenous
and non-Indigenous children, respectively). Hia infection
was limited entirely to Indigenous people ((18) cases
and 14 from the NT), and of those, 13 (72%) were aged
Table I. Invasive Haemophilus inﬂuenzae disease by serotype, Indigenous status
a and age group
Type a Type b Other Nontypeable Not typed Total
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) Rate
b
B5 Indigenous 13 (33) 12 (31) 2 (5) 10 (26) 2 (5) 39 (100) 24.8
Non-Indigenous 0 (0) 9 (41) 3 (14) 8 (36) 2 (10) 22 (100) 2.0
510 Indigenous 0 (0) 1 (20) 2 (40) 2 (40) 0 (0) 5 (100) 6.8
Non-Indigenous 0 (0) 1 (33) 0 (0) 2 (67) 0 (0) 3 (100) 0.3
1160 Indigenous 4 (8) 8 (17) 4 (8) 26 (55) 5 (10) 47 (100) 6.2
Non-Indigenous 0 (0) 1 (3) 5 (15) 24 (73) 4 (10) 33 (100) 0.3
 60 Indigenous 1 (20) 1 (20) 0 (0) 1 (20) 2 (40) 5 (100) 9.3
Non-Indigenous 0 (0) 2 (3) 7 (10) 59 (83) 4 (5) 71 (100) 2.0
Total Indigenous 18 (20) 22 (23) 8 (8) 39 (40) 9 (9) 96 (100) 9.0
Non-Indigenous 0 (0) 13 (9) 15 (12) 92 (71) 10 (7) 129 (100) 0.7
aThere were 13 cases with unknown Indigenous status.
bAverage annual incidence rate of Hi per 100,000 population.
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for NT and SA indigenous children aged B5 years was
10.5/100,000 from 2001 to 2011.
Hi annual incidence rates from Indigenous children
aged B5 years in the NT during 20012011 were much
lower than that found during the period 19851988, with
post-vaccination: pre-vaccination incidence rate ratios
0.03 (0.070.01) for Hib, 0.27 (0.111.25) for Hia, 0.28
for other encapsulated types and 0.45 for non-typeable
isolates (Fig. 2; 95% CI for non-a and non-b types
combined 0.131.40). Serotype data were available for
a smaller proportion of isolates from the earlier
study (74%), compared to recent NT reported cases in
Indigenous children (95%). Adjustment for unknown
serotype, by attributing unknown serotypes in proportion
to the distribution of known serotypes, resulted in post-
to pre-vaccination incidence rate ratios being 0.02, 0.25,
0.21 and 0.33 for Hib, Hia, other encapsulated and non-
typeable isolates, respectively.
Incidence rates by year are shown in Fig. 3, with years
grouped to improve precision. Hi rates in Indigenous
people of all ages were generally lower in 20012003
compared to 20042011, for both encapsulated and non-
typeable types. These differences were significant for all
Hi combined (rate ratio 0.5, 0.30.9), and non-typeable
Hi (0.2, 0.020.7), but not for Hia (0.3, 0.041.4). In non-
Indigenous people, there was no evident trend over time
in total Hi, but an apparent increase in non-typeable
Hi over time was accompanied by apparent decreases
in serotype b and other/unknown types.
Discussion
This study shows no statistically significant trends in
incidence rates of Hia between 2001 and 2011 in the NT
and SA Indigenous people. Rates of invasive Hi in
Indigenous people were lower in the 20012003 period
compared to 20052011, but differences were not sig-
nificant for individual types. The average annual inci-
dence rate for Hia in Indigenous children aged B5 years
from 2001 to 2011 was 11/100,000 in the NTand 7 in SA.
These rates were much lower than what was found in
an audit of NT laboratories in 19851988 (33) (13). As
expected, rates of Hib were much lower in 20012011
compared to 19851988, following the commencement
of widespread vaccination in 1993. In fact, the difference
(98% lower rates in the post-vaccination period) is similar
to the estimated reduction in other populations following
Hib vaccination (14,15). However, rates for non-typeable
Hi and other encapsulated serotypes were also substan-
tially lower in the post-vaccination period, although by
lesser amounts: 75, 79 and 67% lower for Hia, other
encapsulated types and non-typeable Hi, respectively.
Numbers of non-b cases were lower and the decreases
were not statistically significant.
Possible explanations for lower rate point estimates in
more recent times include under-ascertainment of cases
in the post-vaccination period, general improvements in
disease rates due to improved living conditions, changes
in diagnostic practice, and false-positive results in the
pre-vaccine era.
It is possible that the hospital laboratory audit in
19851988 detected a larger proportion of diagnosed
cases than the passive laboratory reporting in place from
2001 to 2011. In fact, the lower rates of Hi in 20012003
may be related to under-ascertainment of cases in the
early years of surveillance. However, the size of the
333
33
7
20
137
11 11 2 9 2 0
50
100
150
200
250
300
350
Hib Hia Other Non-typable Unknown
C
a
s
e
s
 
p
e
r
 
1
0
0
,
0
0
0
 
p
e
r
 
y
e
a
r Northern Territory 1985–1988
Northern Territory 2001–2011
*
* NT 1986–1988, Non-b
Fig. 2. Invasive Haemophilus inﬂuenzae disease by serotype,
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Fig. 3. Incidence of invasive Haemophilus inﬂuenzae disease,
Northern Territory and South Australia, 20002011. (a)
Indigenous; (b) non-Indigenous.
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to vaccination in other settings (14). Any decreased
sensitivity in the later study would be expected to be
equally distributed across serotypes. Therefore, any real
increase in Hia disease relative to other serotypes, in
a surveillance system with decreasing sensitivity, would
result in a change in the relative distribution of serotypes.
There was no evidence of an increase in Hia relative
to other non-b or non-typeable isolates from pre- to post-
vaccination periods.
Evidence of improving social determinants of health
that may have led to lower rates of infectious diseases
include a decline in infant and child mortality in the past
20 years, and an increase in school retention rates
and an improvement in housing for Indigenous com-
pared to non-Indigenous people (1). However, substantial
disparities continue with respect to the social determi-
nants of health and many health indicators including
rates of respiratory disease, particularly in remote areas
(1).
False-positive Hi diagnoses by serum agglutination
assay using CDC or Difco antisera have been identified,
in comparison to PCR, in particular for serotype a (16).
However, the applicability of this to the current study is
unclear as the kits and antisera evaluated by Satola et al.
were not in use in the laboratories involved in this study.
False-positives are unlikely to be prominent in the post-
vaccination Australian data, as PCR confirmation was
frequently conducted at ICPMR, false-positive rates were
found to be negligible, and the same monovalent a, cf
antisera were used at IMVS. The possibility of false-
positive results in the pre-vaccine study from the NT
cannot be discounted, although a very similar serotype
distribution was found in a population of NT Indigenous
children from a similar period tested in another state (17).
As more precise typing methods such as pulsed-field gel
electrophoresis or gene sequence typing are not available,
it is not possible to comment on clonal distribution of Hi
isolates from Australian samples.
The average annual incidence rate of Hia in NT and
SA Indigenous children aged B5 years from 2001 to 2011
(11/100,000) is similar to that reported in the Navajo and
Alaskan Native peoples but appears to be lower than that
reported from northern Canada (Table II). Differences in
surveillance and testing practices cannot be discounted as
explanations for differences in rates.
Conclusion
There is no evidence of increases in invasive disease due
to Hia, other specific non-b types, or non-typeable Hi in
Australian Indigenous children. These data suggest that
the increase in Hia sometime after the introduction of
Hib vaccine, as seen in the North American Arctic
Region, is not common to all populations with high
pre-vaccine rates of invasive Hib disease. However,
small case numbers and the lack of molecular subtyping
and PCR confirmation of pre-vaccine results complicate
comparisons with North American epidemiology.
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